CBL-0137
Tier C — Watch / tradeCBL-0137
Targets：NF-κB, SSRP1, p53
Indications (approved)：Lymphoma, Diffuse intrinsic pontine glioma, Diffuse midline glioma, Solid tumour, 中枢神经系统肿瘤, 皮肤黑色素瘤, Sarcoma, Haematological malignancy
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| CBL-0137 | 1197397-89-9 | 1,1'-(9-(2-(isopropylamino)ethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) hydrochloride |
| CBL-0137-001 | 141-43-5Available | 2-aminoethan-1-ol |
| CBL-0137-002 | 18226-05-6 | N-(2-hydroxyethyl)-4-nitrobenzenesulfonamide |
| CBL-0137-003 | 1370451-29-8 | 2-((4-nitrophenyl)sulfonamido)ethyl methanesulfonate |
| CBL-0137-004 | 43090-97-7 | 1-((4-nitrophenyl)sulfonyl)aziridine |
| CBL-0137-005 | 86-74-8 | 9H-carbazole |
| CBL-0137-006 | - | N-(2-(9H-carbazol-9-yl)ethyl)-4-nitrobenzenesulfonamide |
| CBL-0137-007 | - | N-(2-(3,6-diacetyl-9H-carbazol-9-yl)ethyl)-4-nitrobenzenesulfonamide |
| CBL-0137-008 | 1221238-98-7 | 1,1'-(9-(2-aminoethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) |
| CBL-0137-009 | 1197996-80-7 | 1,1'-(9-(2-(isopropylamino)ethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) |
| Code | CAS No. | Intermediate |
|---|---|---|
| CBL-0137 | 1197397-89-9 | 1,1'-(9-(2-(isopropylamino)ethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) hydrochloride |
| CBL-0137-005 | 86-74-8 | 9H-carbazole |
| CBL-0137-009 | 1197996-80-7 | 1,1'-(9-(2-(isopropylamino)ethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) |
| CBL-0137-010 | 109-56-8 | 2-(isopropylamino)ethanol |
| CBL-0137-011 | 610309-73-4 | tert-butyl (2-hydroxyethyl)(isopropyl)carbamate |
| CBL-0137-012 | 40482-44-8 | 3-isopropyloxazolidin-2-one |
| CBL-0137-013 | 3403-70-1 | 1,1'-(9H-carbazole-3,6-diyl)bis(ethan-1-one) |
Frequently asked questions
What are the approved indications of CBL-0137?
Approved indications include: Lymphoma, Diffuse intrinsic pontine glioma, Diffuse midline glioma, Solid tumour, 中枢神经系统肿瘤, 皮肤黑色素瘤, Sarcoma, Haematological malignancy.
When does the CBL-0137 patent expire?
No public expiry year is available for CBL-0137 yet; this page updates once verified.
How many synthesis routes are recorded for CBL-0137?
2 synthesis routes are recorded; the shortest is 5 steps with 3.5 g (CBL-0137) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy CBL-0137 intermediates?
1 intermediate CAS of CBL-0137 are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for CBL-0137 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21